Abstracts tagged "Still’s disease and tocilizumab"

Abstract Number: 788 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tocilizumab In Refractory Adult-Onset Still’s Disease: Multicenter Study Of 32 Patients
Francisco Ortiz-Sanjuan¹, Ricardo Blanco², Javier Narvaez³, Esteban Rubio Romero⁴, Alejandro Olivé⁵, Santos Castañeda⁶, Adela Gallego Flores⁷, M. Victoria Hernández⁸, Cristina Mata¹, Inmaculada Ros Vilamajo⁹, Alberto Sifuentes Giraldo¹⁰, M Caracuel¹¹, Mercedes Freire¹², Catalina Gómez Arango¹³, José Llobet¹⁴, Sara Manrique Arija¹⁵, Carlos Marras¹⁶, Concepcion Moll Tuduri¹⁷, Chamaida Plasencia Rodriguez¹⁸, Rosa Roselló¹⁹, Ana Urruticoechea²⁰, Maria Luisa Velloso Feijoo²¹, Javier Loricera¹, Vanesa Calvo-Rio¹ and Miguel A González-Gay²², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Hospital Marques de Valdecilla, Santander, Spain, ³Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, ⁵Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁶Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, ⁷Rheumatology, Hospital de Mérida, Mérida, Spain, ⁸Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁹Hospital Son Llàtzer, Palma de Mallorca, Spain, ¹⁰Rheumatology, H Ramón y Cajal, Madrid, Spain, ¹¹Rheumatology., Hospital de Córdoba., Córdoba, Spain, ¹²Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹³HU Basurto, Bilbao, Spain, ¹⁴H Sant Pau, Barcelona, Spain, ¹⁵HRU Carlos Haya, Málaga, Spain, ¹⁶Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁷Hospital Mateu Orfila. Menorca. Spain, Mahón (Menorca), Spain, ¹⁸HU La Paz, Madrid, Spain, ¹⁹H San Jorge, Huesca, Spain, ²⁰Hospital Can Misses, Ibiza, Spain, ²¹H Valme, Sevilla, Spain, ²²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Adult-onset Still's disease (AOSD) is frequently refractory to standard immunosuppressive drugs and it may require biological therapy. Tocilizumab (TCZ) has demonstrated efficacy in clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].